Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2020-06-10 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It includes a press release about a COVID-19 clinical trial application submission. The document is relatively short (2138 characters) and primarily serves as a regulatory update rather than a full financial report or detailed presentation. It does not contain financial statements, management discussion, or detailed financial data. Form 6-K filings typically fall under general regulatory announcements for foreign issuers. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-06-10 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by a foreign private issuer, RedHill Biopharma Ltd., submitted to the SEC. Form 6-K is used by foreign private issuers to provide current reports of material information that is not required to be filed on Form 20-F. The text includes a press release update on COVID-19 and other development programs, but the document itself is a regulatory filing reporting this information. The document length is short (2190 characters), and it is a standalone filing rather than a full report like an annual or interim report. According to the classification rules, Form 6-K filings are best categorized under Regulatory Filings (RNS) as they are general regulatory announcements and do not fit other specific categories such as Annual Report or Interim Report. Therefore, the correct classification is Regulatory Filings (RNS).
2020-06-08 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F. The document includes a press release about a presentation at BIO Digital but does not contain financial statements or detailed financial analysis. The document length is 2086 characters, which is relatively short and primarily serves as a regulatory filing to disclose material information. It does not fit the definitions of Annual Report, Interim Report, Earnings Release, or other detailed financial or management reports. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-06-01 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The document includes a press release about a presentation at a healthcare conference, but does not contain financial statements or detailed financial data. The document length is 2113 characters, which is relatively short and mainly serves as a regulatory filing to report material information. It does not qualify as an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or any other detailed financial report. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other categories.
2020-05-28 English
FORM 6-K
Interim / Quarterly Report Classification · 90% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release with Q1/2020 financial results and condensed consolidated interim unaudited financial information for the three months ended March 31, 2020. Form 6-K is used by foreign private issuers to report material information between annual reports. The document length is 2298 characters, which is relatively short and primarily serves as a report submission rather than a full detailed interim report. The presence of interim financial information suggests it relates to a quarterly or interim report, but since it is a Form 6-K filing (which is a regulatory filing for foreign issuers), and the document includes financial data, it aligns best with the category of Interim / Quarterly Report (IR). The document is not merely an announcement or certification but contains substantive financial data for the quarter. Therefore, the classification is IR with high confidence.
2020-05-27 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about hosting a first quarter financial results conference call. The document is short (2124 characters) and primarily serves as a regulatory filing to report this event. It does not contain actual financial statements or detailed financial data, nor is it a transcript of the call itself. According to the rules, Form 6-K filings are typically regulatory filings for foreign issuers to report material information between annual reports. Therefore, this document fits best under Regulatory Filings (RNS).
2020-05-20 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.